Changes in cellular proliferation and plasma products are associated with liver failure

doi:10.4254/wjh.v8.i32.1370

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7352)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-6) series.

Item

Count

PDF

446

WORD

251

HTML

3047

Figures (1-4)

185

Tables (1-6)

172

Sum=4101

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1011

Download

2240

Sum=3251

Nov 18, 2016 (publication date) through May 6, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Hepatol. Nov 18, 2016; 8(32): 1370-1383
Published online Nov 18, 2016. doi: 10.4254/wjh.v8.i32.1370

Table 1 Clinical characteristics of the studied population n (%)

	Acute liver failure (n = 16)	Acute hepatitis (n = 46)	Healthy control (n = 22)
Age (yr)
Mean ± SD	24.88 ± 21.52	21.21 ± 10.32	24.64 ± 8.79
25%, 75%	9.25, 49	9.1, 29.75	15.2, 47
Gender
Male	6 (37.50)	25 (54.34)	9 (40.9)
Diagnosis
Hepatitis A	11 (68.75)	38 (82.60)	0
Drug toxicity	2 (12.50)	2 (4.34)	0
Indeterminate	3 (18.75)	6 (13.04)	0
Liver enzymes
AST (UI/L)	1095.5 ± 1460	344.5 ± 444.9	21.68 ± 4.87
ALT (UI/L)	806.12 ± 639.11	517.90 ± 884.30	14.36 ± 4.50
Total bilirubin (mg/dL)	21.47 ± 10.48	10.01 ± 6.88	0.85 ± 0.09
Coma grade
0-I	3 (18.75)	0	0
II-IV	13 (81.25)	0	0
Coagulopathy
INR (mean ± SD)	4.88 ± 0.99	1.16 ± 0.04	0.98 ± 0.06
Outcome
Survived	6 (46.15)	46 (100.00)	22 (100)
Died	10 (53.84)	0	0

INR: International normalized ratio; SD: Standard deviation; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.

Table 2 Systemic inflammatory products in the plasma samples from patients with acute hepatitis or acute liver failure and healthy subjects

Plasma variables	HC (n = 22)	AH (n = 49)	ALF (n = 13)	HC vs AH^a	HC vs ALF	AH vs ALF
IL-6 (pg/mL)	15.07 ± 25.92 (3.58-26.57)¹	68.93 ± 109.7 (38.39-99.46)	509.30 ± 678.70 (147.6-870.9)	0.0009	< 0.0001	< 0.0001
IL-8 (pg/mL)²	ND	10.50 ± 20.05 (4.92-16.09)	144.70 ± 437.6 (-88.45-377.9)	< 0.001	< 0.0001	ns
IL-10 (pg/mL)	1.81 ± 5.58 (-0.66-4.28)	17.28 ± 51.97 (2.81-31.75)	249.60 ± 379.60 (47.35-451.9)	0.0006	< 0.0001	< 0.0001
IFNγ (pg/mL)	4.80 ± 18.00 (-3.18-12.79)	113.0 ± 265.33 (39.1-186.8)	229.70 ± 342.20 (47.37-412.1)	0.0075	< 0.0001	0.0016
TNFα (pg/mL)	1.08 ± 2.38 (0.02-2.13)	27.25 ± 64.05 (9.42-45.08)	179.40 ± 161.40 (93.42-265.4)	ns	< 0.0001	< 0.0001
mtDNA (ng/100 μL plasma)	81.79 ± 121.6 (27.88-135.7)	159.6 ± 202.2 (64.99-254.3)	4228.00 ± 4286.0 (1944-6512)	0.0131	< 0.0001	0.0008

¹Mean ± standard deviation (95%CI);

²IL-8 levels in the plasma samples were evaluated only by the Kruskal-Wallis test.

^aP < 0.05. The differences between the acute liver failure patients, the self-limited acute hepatitis patients and the healthy controls were evaluated by intergroup comparisons using the Mann-Whitney U-test. IL: Interleukin; IFNγ: Interferon gamma; TNFα: Tumor necrosis factor alpha; mtDNA: Total mitochondrial DNA; ND: Not detectable; ns: Not significant; HC: Healthy control; AH: Acute hepatitis (viral plus non-viral etiologies); ALF: Acute liver failure (viral plus non-viral etiologies).

Table 3 Potential clinical and inflammatory parameters as indicators of acute liver failure syndrome and death

	Cut-off	Adjusted OR	95%CI	P value
Plasma variables¹
IL-6 (pg/mL)	> 197.6	1.36	0.04-40.27	0.856
IL-10 (pg/mL)	> 55.77	18.86	1.38-257.94	0.028
TNFα (pg/mL)	> 122.6	4.42	0.185-105.93	0.359
mtDNA (ng/100 μL plasma)	> 174	320.54	14.42-7123.33	0.000
Plasma variables²
IL-6 (pg/mL)	> 473.2	2.27	0.19-26.92	0.515
IL-8 (pg/mL)	> 66.30	10.42	1.54-70.45	0.016
IL-10 (pg/mL)	> 95.71	8.01	1.26-50.97	0.027
TNFα (pg/mL)	> 313.7	0.27	0.03-2.17	0.220
mtDNA (ng/100 μL plasma)	> 405.3	12.11	2.57-57.07	0.002
INR	> 2.12	29.88	5.44-164.19	0.000

¹Multivariate analysis from clinical and inflammatory parameters associated with ALF;

²Multivariate analysis from clinical and inflammatory parameters associated with death. OR: Odds ratio; IL: Interleukin; IFNγ: Interferon gamma; TNFα: Tumor necrosis factor alpha; mtDNA: Total mitochondrial DNA; ALF: Acute liver failure; INR: International normalized ratio.

Table 4 Variables from the mitogen-stimulated peripheral blood mononuclear cell phenotypes from patients with acute hepatitis A infection and healthy subjects

Phenotypes/cytokines (PHA/LPS)	HC (n = 10)	AH (n = 8)	ALF (n = 8)	HC vs AH	HC vs ALF	AH vs ALF
PI of CD3⁺	133.1 ± 71.12	44.4 ± 25.83	17.48 ± 5.94	0.0155	0.0021	0.0426
	(95.19-171.0)	(22.80-65.99)	(11.24-23.72)
CD4⁺CD25⁺FoxP3⁺ (%)	17.23 ± 9.74	17.08 ± 5.37	5.99 ± 2.80	ns	0.0009	0.0003
	(12.03-22.42)	(12.59-21.57)	(3.65-8.33)
CD4⁺CD29⁺CD44⁺ (%)	38.63 ± 18.37	20.75 ± 7.82	10.22 ± 4.74	0.0062	< 0.0001	0.0047
	(28.84-48.42)	(14.21-27.29)	(6.25-14.18)
CD8⁺CD29⁺CD44⁺ (%)	39.76 ± 19.91	37.56 ± 25.01	9.03 ± 4.59	ns	0.0002	0.0104
	(29.15-50.36)	(16.74-58.57)	(5.18-12.88)
CD3^-CD56⁺CD16^- (%)	8.31 ± 6.75	4.19 ± 2.28	0.50 ± 0.37	ns	0.0006	0.0009
	(2.07-14.56)	(2.08-6.30)	(0.15-0.84)
CD3^-CD56^lowCD16⁺ (%)	12.70 ± 8.93	8.52 ± 5.68	1.11 ± 0.66	ns	0.0012	0.0018
	(4.44-20.96)	(3.26-13.78)	(0.50-1.72)
CD3⁺CD56⁺CD16⁺ (%)	13.66 ± 3.54	7.20 ± 5.28	1.83 ± 1.06	0.0117	< 0.0001	0.0070
	(11.77-15.55)	(2.79-11.63)	(0.94-2.72)
IL-6 (pg/mL)	2625.33 ± 3320	565.7 ± 313.3	156.8 ± 173.9	0.0155	< 0.0001	0.0070
	(856.5-4394)	(303.8-827.6)	(11.40-302.2)
TNFα (pg/mL)	1675.20 ± 623.4	1405.0 ± 324.3	145.3 ± 107.9	ns	< 0.0001	0.0002
	(1343-2007)	(1134-1676)	(55.09-235.5)
IL-10 (pg/mL)	528.86 ± 755.1	269.5 ± 145.8	188.4 ± 267.1	ns	0.0454	ns
	(126.5-931.2)	(147.6-391.5)	(-16.88-393.7)
IFNγ (pg/mL)	3379.1 ± 1869	2467.0 ± 2787	1249.0 ± 2067	ns	0.0205	ns
	(2383-4375)	(137.1-4798)	(-479.2-2977)
IL-8 (pg/mL)	273.9 ± 116.3	274.2 ± 148.5	151.0 ± 156.4	ns	0.0205	0.0379
	(211.9-335.9)	(150.0-398.3)	(20.21-281.8)
IL-17 (pg/mL)	73.81 ± 107.0	31.55 ± 35.58	4.16 ± 3.20	ns	0.0029	0.0116
	(16.81-130.8)	(1.80-61.30)	(1.49-6.84)

The differences between the hepatitis A-induced acute liver failure (ALF) patients, the self-limited acute hepatitis A (AH) patients, and the healthy control (HC) subjects were evaluated by intergroup comparisons using the Mann-Whitney U-test. The significance cutoff for all statistical analyses was defined as P < 0.05. IL: Interleukin; IFNγ: Interferon gamma; TNFα: Tumor necrosis factor alpha; ns: Not significant; PI: Proliferation index.

Table 5 Variables from hepatitis A virus Ag-stimulated peripheral blood mononuclear cell phenotypes from patients with acute hepatitis A infection and healthy subjects

Phenotypes/cytokines (HAVAg)	HC (n = 10)	AH (n = 8)	ALF (n = 8)	HC vs AH	HC vs ALF	AH vs ALF
PI of CD3⁺	1.09 ± 0.85	3.15 ± 1.92	3.34 ± 2.29	0.0053	0.0044	ns
	(0.64-1.55)	(1.54-4.76)	(1.42-5.25)
CD4⁺CD25⁺FoxP3⁺ (%)	0.85 ± 0.96	1.0 ± 0.97	3.19 ± 1.49	ns	0.0011	0.0070
	(0.34-1.37)	(0.18-1.81)	(1.95-4.44)
CD4⁺CD29⁺CD44⁺ (%)	11.99 ± 6.43	27.93 ± 8.16	5.46 ± 5.92	0.0008	0.0077	0.0006
	(8.55-15.42)	(21.1-34.76)	(0.50-10.42)
CD8⁺CD29⁺CD44⁺ (%)	12.65 ± 4.31	30.13 ± 6.74	36.05 ± 10.59	0.0001	0.0001	ns
	(10.35-14.95)	(24.49-35.77)	(27.19-44.90)
CD3^-CD56⁺CD16^- (%)	0.19 ± 0.20	0.30 ± 0.19	1.33 ± 0.85	ns	0.0009	0.0005
	(0.05-0.34)	(0.13-0.46)	(0.62-2.04)
CD3^-CD56^lowCD16⁺ (%)	4.28 ± 2.22	10.09 ± 8.94	14.24 ± 11.81	ns	ns	ns
	(2.70-5.87)	(2.61-17.5)	(4.36-24.12)
CD3⁺CD56⁺CD16⁺ (%)	1.67 ± 2.71	4.25 ± 4.06	15.06 ± 7.74	0.0110	0.0003	0.0019
	(0.22-3.12)	(0.85-7.65)	(8.58-21.53)
IL-6 (pg/mL)	50.49 ± 76.14	76.41 ± 93.18	139.7 ± 165.9	ns	ns	ns
	(9.92-91.06)	(-1.46-154.3)	(0.98-278.4)
TNFα (pg/mL)	92.49 ± 133.4	23.96 ± 28.92	1.63 ± 1.01	ns	0.0089	0.0098
	(21.42-163.6)	(-0.21-48.14)	(0.78-2.48)
IL-10 (pg/mL)	10.39 ± 13.97	52.78 ± 62.06	164.3 ± 75.56	0.0297	0.0001	0.0148
	(2.94-17.84)	(0.89-104.7)	(101.1-227.5)
IFNγ (pg/mL)	0.88 ± 1.08	106.6 ± 183.9	1095 ± 1962	0.0035	0.0001	0.0499
	(0.30-1.46)	(-47.14-260.4)	(-546-2735)
IL-8 (pg/mL)	88.64 ± 45.40	148.9 ± 54.77	150.2 ± 72.19	0.0131	0.0110	ns
	(64.44-112.8)	(103.1-194.7)	(89.84-210.5)
IL-17 (pg/mL)	3.36 ± 3.75	32.61 ± 38.30	7.58 ± 5.43	0.0008	ns	0.0499
	(1.36-5.36)	(0.59-64.64)	(3.05-12.13)

The differences between the hepatitis A-induced acute liver failure (ALF) patients, the self-limited acute hepatitis A (AH) patients and the healthy control (HC) subjects were evaluated by intergroup comparisons using the Mann-Whitney U-test. The significance cutoff for all statistical analyses was defined as P < 0.05. IL: Interleukin; IFNγ: Interferon gamma; TNFα: Tumor necrosis factor alpha; ns: Not significant; PI: Proliferation index.

Table 6 Variables from mitogen-stimulated peripheral blood mononuclear cells from non-viral acute hepatitis patients and healthy control subjects

Phenotypes/cytokines (PHA/LPS)	HC (n = 10)	AH (n = 8)	ALF (n = 5)	HC vs AH	HC vs ALF	AH vs ALF
PI of CD3⁺	133.1 ± 71.12	173.3 ± 91.84	268.4 ± 101.6	ns	ns	ns
	(95.19-171.0)	(96.51-250.1)	(142.3-394.5)
CD4⁺CD25⁺FoxP3⁺ (%)	17.23 ± 9.74	15.82 ± 8.13	6.84 ± 5.12	ns	ns	ns
	(12.03-22.42)	(9.02-22.62)	(0.48-13.2)
CD4⁺CD29⁺CD44⁺ (%)	38.63 ± 18.37	21.84 ± 7.50	36.67 ± 14.54	ns	ns	ns
	(28.84-48.42)	(15.56-28.11)	(18.61-54.73)
CD8⁺CD29⁺CD44⁺(%)	39.76 ± 19.91	22.26 ± 11.16	29.59 ± 15.21	ns	ns	ns
	(29.15-50.36)	(12.92-31.59)	(10.71-48.47)
CD3^-CD56⁺CD16^- (%)	8.31 ± 6.75	6.33 ± 4.13	17.22 ± 4.94	ns	0.0289	0.0030
	(2.07-14.56)	(2.88-9.79)	(13.09-21.35)
CD3^-CD56^lowCD16⁺ (%)	12.70 ± 8.93	11.38 ± 4.67	27.66 ± 3.49	ns	0.0061	0.007
	(4.44-20.96)	(7.05-15.71)	(22.11-33.21)
CD3⁺CD56⁺CD16⁺ (%)	13.66 ± 3.54	11.63 ± 3.01	8.52 ± 4.97	ns	ns	ns
	(11.77-15.55)	(9.11-14.15)	(2.35-14.70)
IL-6 (pg/mL)	2625.33 ± 3320	966 ± 622.6	1309 ± 851.6	ns	ns	ns
	(856.5-4394)	(445.5-1486.0)	(251.60-2366)
TNFα (pg/mL)	1675.20 ± 623.4	1497 ± 219.8	3217 ± 991.5	ns	0.0044	0.0016
	(1343-2007)	(1313-1681)	(1986-4448)
IL-10 (pg/mL)	528.86 ± 755.1	217.1 ± 159.1	152.1 ± 126.4	ns	ns	ns
	(126.5-931.2)	(84.12-350.2)	(-4.89-309.0)
IFNγ (pg/mL)	3379.1 ± 1869	2257 ± 2872	1378 ± 2533	ns	ns	ns
	(2383-4375)	(-143.3-4658)	(-1767-4524)
IL-8 (pg/mL)	273.9 ± 116.3	293.9 ± 120.2	733.1 ± 404.8	ns	0.0267	ns
	(211.9-335.9)	(193.4-394.4)	(230.4-1236)
IL-17 (pg/mL)	73.81 ± 107.0	36.31 ± 34.62	62.73 ± 5.78	ns	ns	ns
	(16.81-130.8)	(7.36-65.25)	(55.55-69.91)

The differences between the non-viral acute liver failure (ALF) patients, the self-limited acute hepatitis (AH) patients, and the healthy control (HC) subjects were evaluated by intergroup comparisons using the Mann-Whitney U-test. The significance cutoff for all statistical analyses was defined as P < 0.05. IL: Interleukin; IFNγ: Interferon gamma; TNFα: Tumor necrosis factor alpha; PI: Proliferation index; HC: Healthy control; ns: Not significant.

Citation: Melgaço JG, Soriani FM, Sucupira PHF, Pinheiro LA, Vieira YR, de Oliveira JM, Lewis-Ximenez LL, Araújo CCV, Pacheco-Moreira LF, Menezes GB, Cruz OG, Vitral CL, Pinto MA. Changes in cellular proliferation and plasma products are associated with liver failure. World J Hepatol 2016; 8(32): 1370-1383
URL: https://www.wjgnet.com/1948-5182/full/v8/i32/1370.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i32.1370